Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial
The British Journal of Psychiatry · 2025-07 · 227 (1) · 473-480
DOI: 10.1192/bjp.2025.84 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The British Journal of Psychiatry, online erschienen am 09.05.2025. Verfasst von Yunsheng He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vanda Pharmaceuticals, Washington, DC, USA. Hauptthemen laut MEDLINE: alpha7 Nicotinic Acetylcholine Receptor, Anti-Anxiety Agents, Anxiety, Anxiety Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite the high prevalence of social and performance anxiety, current treatments do not meet the full needs of patients. Development of novel anxiolytics with rapid onset of action for on-demand treatment of social and performance anxiety is an active area of clinical research.
Aims
To examine the anxiolytic effect of VQW-765, an α7-nAChR agonist, in subjects with performance anxiety.
Method
We conducted a randomised, double-blind, placebo-controlled trial of 230 adults with a history of public speaking anxiety. Participants were randomly assigned to receive a single oral dose of 10 mg VQW-765 ( n = 116) or placebo ( n = 114), followed by a Trier Social Stress Test (TSST). Anxiety levels were assessed by the Subjective Units of Distress Scale (SUDS). Heart rate was monitored during the TSST. Plasma concentration of VQW-765 was measured after the TSST.
Results
Subjects receiving VQW-765 showed a trend of improvement in intensity of anxiety, as measured by the SUDS, during the performance phase of a TSST compared with placebo ( P = 0.1443). Females showed a larger magnitude and significant response to VQW-765 ( P = 0.034). The pharmacokinetic/pharmacodynamic analysis observed an inverted U-shaped exposure–response relationship. Subjects in the middle 50% quantiles of VQW-765 plasma concentration showed significant improvement in the SUDS rating compared with placebo ( P = 0.033); however, subgroup analysis revealed this was true only for females ( P = 0.005). VQW-765 was safe and well tolerated.
Conclusions
This is the first study showing anxiolytic effect of an α7-nAChR agonist in humans. VQW-765 is a promising candidate to be developed for on-demand treatment of social anxiety disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanda Pharmaceuticals, Washington, DC, USA.
ORCID-Profile: Yunsheng He
Zitieren
APA
He, Y., Polymeropoulos, C. M., Mohrman, M. A., Truslow, S. O., Xiao, C., Wu, Y., Birznieks, G., & Polymeropoulos, M. H. (2025). Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. The British Journal of Psychiatry, 227(1), 473-480. https://doi.org/10.1192/bjp.2025.84
Vancouver
He Y, Polymeropoulos CM, Mohrman MA, Truslow SO, Xiao C, Wu Y, et al. Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. The British Journal of Psychiatry. 2025;227(1):473-480. doi:10.1192/bjp.2025.84
BibTeX
@article{He2025,
author = {He, Yunsheng and Polymeropoulos, Christos M and Mohrman, Michael A and Truslow, Sunny O and Xiao, Changfu and Wu, Yukun and Birznieks, Gunther and Polymeropoulos, Mihael H},
title = {Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial},
journal = {The British Journal of Psychiatry},
year = {2025},
volume = {227},
number = {1},
pages = {473--480},
doi = {10.1192/bjp.2025.84}
}
EUVIMED